NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Acrivon Therapeutics, Inc. (ACRV) Stock Analysis

Acrivon Therapeutics, Inc. (ACRV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ACRV

$2.13

+$0.07 (+3.40%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACRV with… →

ACRV Key Statistics

As of Sep 4, 2026
Trading
Open
$2.06
Previous Close
$2.06
Day's Range
2.06–2.14
52-Week Range
1.27–3.56
Volume
184.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.93
Valuation
Market Cap
$91.28M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.95
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$77.91M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
42.85M
1-Year Return
+63.85%
Dividend and dates
Avg Volume
388.62K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ACRV Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−11.62%
2025−59.97%
2024+22.36%
2023−57.29%
2022 (partial year)−30.77%

As of September 4, 2026.

ACRV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$77.91M—
2024$0.00−$80.56M—
2023$0.00−$60.39M—
2022$0.00−$31.17M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$84.11M−$77.91M—
2024$0.00—−$89.20M−$80.56M—
2023$0.00—−$67.10M−$60.39M—
2022$0.00—−$32.66M−$31.17M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACRV Valuation vs Biotechnology Median

Median of 656 stocks
MetricACRVBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Acrivon Therapeutics, Inc. (ACRV) is capitalised at $91.28M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 74 employees.

ACRV last closed at $2.13 on September 4, 2026. That is +$0.07 (+3.40%) against the previous close. The 52-week range on file runs from $1.27 to $3.56. The latest close sits 67.72% above that 52-week low.

Financial Health

In fiscal 2025, Acrivon Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $77.91M. Profit margin runs at 0%. Trailing earnings per share are −1.95.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +63.85%. Across 3 years the annualized return works out at −43.34%. The reported beta is 1.93. Daily returns over the trailing 3 years annualize to a volatility of 104.76%.

Growth & Income

No dividend is on file for ACRV.

The strongest complete calendar year on file is 2024 at +22.36%; the weakest is 2025 at −59.97%. Of the 3 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −11.62% year to date.

Peer Comparison

Acrivon Therapeutics, Inc. (ACRV) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Acrivon Therapeutics, Inc. ACRV $91.28M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Acrivon Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Visit website →